Table 1.
Suggested MBL effect | Clinical association | Reference |
---|---|---|
Harmful | “High MBL” genotypes more frequent and higher levels of MBL in sera of patients with acute MI compared to controls | Pesonen et al. [72] |
Higher levels in patients with STEMI and LVEDF <35% comparing to controls with STEMI and LVEDF >35% | Haahr-Pedersen et al. [73] | |
High serum levels associated with increased postinfarct ventricular ESV and EDV in STEMI patients | Schoos et al. [75] | |
Low serum levels associated with lower mortality | Trendelenburg et al. [76] | |
| ||
Protective | High serum level associated with decreased risk of MI | Saevarsdottir et al. [80] |
“MBL deficient” genotypes connected with higher likelihood of MI at middle age | Vengen et al. [81] |